NCT01768338View on ClinicalTrials.gov

Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

August 3, 2017

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Ofatumumab combined with SB-485232

Ofatumumab with escalating doses of SB-485232

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Michael John Robertson

OTHER